Cas no 59-01-8 (Kanamycin A)

Kanamycin A is an aminoglycoside antibiotic derived from Streptomyces kanamyceticus. It exhibits broad-spectrum activity against Gram-negative and some Gram-positive bacteria by binding to the 30S ribosomal subunit, inhibiting protein synthesis. Kanamycin A is particularly effective against Mycobacterium tuberculosis and other resistant strains when used in combination therapies. Its stability in aqueous solutions and high solubility make it suitable for both research and clinical applications, including cell culture and selective media preparation. The compound is often utilized in molecular biology for selecting transgenic organisms due to its reliable efficacy. Proper handling is essential to minimize potential ototoxicity and nephrotoxicity risks.

Kanamycin A structure

Product Name:Kanamycin A

CAS No:59-01-8

MF:C₁₈H₃₆N₄O₁₁

MW:484.498645782471

MDL:MFCD00070289

CID:93257

PubChem ID:6032

Update Time:2025-06-15

Kanamycin A Chemical and Physical Properties

Names and Identifiers

- kanamycin
- KANAMYCIN A
- KANAMYCIN BASE
- 4))-2-deoxy-y-alpha-d-glucopyranosyl-(
- 4,6-diamino-2-hydroxy-1,3-cyclohexane3,6’diamino-3,6'-dideoxydi-alpha-d-gluc
- 4,6-diamino-2-hydroxy-1,3-cyclohexane3,6’diamino-3,6’-dideoxydi-alpha-d-glucos
- d-deoxydi
- Kanamycin Monosulfate
- KANAMYCIN BASE ENTERPRISE STANDARD
- d-xydi
- gentamicin A
- kanamicina
- kanamycin from Streptomyces kanamyceticus
- KanamycinMonosulfateA
- Kannamycin Monosulfate
- 4,6-diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-d-glucos
- O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy-alpha-D-glucopyranosyl-(1→4)]-2-deoxy-D-streptamine
- 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'-diamino-3,6'-dideoxydi-alpha-D-glucoside
- Kanacin
- KANAMYCIN A [WHO-IP]
- D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-2-deoxy-
- (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside
- Kanamycins
- KANAMYCIN A [HSDB]
- (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
- Kanamycin sulfate, Antibiotic for Culture Media Use Only
- Kanamycin A Deuterated
- AS-14003
- 8063-07-8
- UNII-RUC37XUP2P
- A07AA08
- EINECS 200-411-7
- DTXSID2041171
- 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
- BSPBio_000607
- D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-
- EN300-19735925
- S01AA24
- Kanamycin Complex
- (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2H-pyran-3,4,5-triol
- NCGC00179506-01
- BPBio1_000669
- KM (the Antibiotic)
- Kantrex (1:1 sulfate)
- 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside
- IDI1_000024
- SBUJHOSQTJFQJX-NOAMYHISSA-N
- Kanamycinum
- KAN
- KanamycinA
- Prestwick3_000394
- SMP2_000007
- DivK1c_000024
- 59-01-8
- J01GB04
- Kanamycinum [INN-Latin]
- (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside
- DTXCID503184
- CHEBI:6104
- D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-
- Kanamycin A monosulfate
- AKOS025293505
- Klebcil (1:1 sulfate)
- Kanamycine
- Kanamycin,(S)
- HY-16566
- Kanamycinum (Latin)
- UNII-EQK9Q303C5
- KANAMYCIN A [MI]
- Q27094615
- Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-
- Kanamycin [INN:BAN]
- RUC37XUP2P
- NS00098990
- EINECS 232-512-7
- D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-
- BRN 0061647
- CHEBI:17630
- D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.4)]-2-deoxy-
- SCHEMBL2735
- O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine
- Liposomal Kanamycin
- 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
- K-0250
- HSDB 3107
- ANTIBIOTIC COMPLEX FROM STREPTOMYCES KANAMYCETICUS CONTAINING KANAMYCIN A (MAJOR), KANAMYCIN B AND KANAMYCIN C
- CS-0006792
- Kanamycine [INN-French]
- GTPL12132
- AB00513827
- Kanamicina [Italian]
- KBio1_000024
- BRD-K08327065-065-01-9
- BDBM50031282
- (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]tetrahydropyran-3,4,5-triol
- DB01172
- NINDS_000024
- (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-3-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}oxane-3,4,5-triol
- O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine
- EQK9Q303C5
- D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-2-deoxy-
- NCGC00179506-05
- CHEMBL1384
- C01822
- DTXSID3023184
- BRD-K08327065-065-04-3
- 1174286-24-8
- Kanamycin A
- MDL： MFCD00070289
- Inchi： 1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
- InChI Key： SBUJHOSQTJFQJX-NOAMYHISSA-N
- SMILES： O([C@@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)N)O)[C@H]1[C@@H](C[C@@H]([C@H]([C@@H]1O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@@H](CN)O1)O)O)O)N)N

Computed Properties

Exact Mass: 484.23800
Monoisotopic Mass: 484.238058
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 11
Hydrogen Bond Acceptor Count: 15
Heavy Atom Count: 33
Rotatable Bond Count: 6
Complexity: 638
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 15
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 283
XLogP3: -6.9

Experimental Properties

Density: 1.62±0.1 g/cm3 (20 oC 760 Torr),
Melting Point: Not available
Boiling Point: 581.13°C (rough estimate)
Flash Point: 442.3±34.3 °C
Refractive Index: 1.6700 (estimate)
Solubility: Soluble (998 g/l) (25 o C),
PSA: 282.61000
LogP: -4.49020
Specific Rotation: D24 +146° (0.1N H2SO4)
Vapor Pressure: 0.0±6.5 mmHg at 25°C

Kanamycin A Security Information

Signal Word：warning
Hazard Statement： H303+H313+H333
Warning Statement： P264+P280+P305+P351+P338+P337+P313
WGK Germany：2
Safety Instruction： H303+H313+H333
Toxicity：LD50 i.v. in mice: 583 mg/kg (Wakazawa)
Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

Kanamycin A Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	K275316-25g	Kanamycin A	59-01-8	97%	25g	￥1853.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	K275316-1g	Kanamycin A	59-01-8	97%	1g	￥154.90	2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	K275316-5g	Kanamycin A	59-01-8	97%	5g	￥535.90	2023-09-02
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.	ajci17272-5g	Kanamycin A	59-01-8	98%	5g	￥768.00	2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.	ajci17272-10g	Kanamycin A	59-01-8	98%	10g	￥1117.00	2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.	ajci17272-25g	Kanamycin A	59-01-8	98%	25g	￥1857.00	2023-09-09
TRC	K137495-100mg	Kanamycin A	59-01-8		100mg	$ 159.00	2023-09-07
TRC	K137495-250mg	Kanamycin A	59-01-8		250mg	$ 357.00	2023-09-07
TRC	K137495-1g	Kanamycin A	59-01-8		1g	$ 1216.00	2023-09-07
Biosynth	AK30116-50 mg	Kanamycin A	59-01-8		50mg	$1,000.00	2023-01-05

Kanamycin A Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:59-01-8)卡那霉素堿

Order Number:LE27017092;LE16147

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 13:01

Price ($):discuss personally

Email:[email protected]

Zhengzhou Baoyu Pharmaceutical Co., Ltd.

Gold Member

Audited Supplier

(CAS:59-01-8)KANAMYCIN

Order Number:LE228

Stock Status:in Stock

Quantity:5KG/1KG/25KG/100KG

Purity:99% HPLC

Pricing Information Last Updated:Thursday, 14 August 2025 14:44

Price ($):negotiated

Email:[email protected]

Kanamycin A Related Literature

1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies

Jason Wan Lab Chip, 2020,20, 4528-4538
2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications

Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.

LarsBanko,AlfredLudwig
4. Excitation energies from ground-state density-functionals by means of generator coordinates

A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field

XuxinCheng,XiaomingChen,PengyuanFan

Related Categories

Additional information on Kanamycin A

Introduction to Kanamycin A (CAS No. 59-01-8)

Kanamycin A, a significant compound with the chemical identifier CAS No. 59-01-8, is a cornerstone in the field of antibiotics and has been extensively studied for its pharmacological properties. This natural product, derived from the bacterium Streptomyces kanamyceticus, has garnered considerable attention due to its broad-spectrum antimicrobial activity. The molecular structure of Kanamycin A consists of a complex glycoside, featuring multiple sugar units and an aminoglycoside core, which contributes to its potent effects against various Gram-negative bacteria.

The Kanamycin A molecule exhibits a unique mechanism of action by interfering with bacterial protein synthesis. It binds to the 30S ribosomal subunit, causing misreading of the genetic code and ultimately leading to the production of non-functional proteins. This mechanism has made Kanamycin A a valuable tool in both clinical settings and research laboratories. Its effectiveness against resistant bacterial strains has been a subject of ongoing investigation, particularly in light of the growing global concern over antibiotic resistance.

Recent advancements in synthetic chemistry have enabled the development of semi-synthetic derivatives of Kanamycin A, which aim to enhance its efficacy while reducing side effects. These derivatives, such as Amikacin and Gentamicin, have been instrumental in treating severe infections caused by multidrug-resistant bacteria. The study of these derivatives has provided insights into the structural modifications that can improve pharmacokinetic properties without compromising therapeutic benefits.

In the realm of academic research, Kanamycin A continues to be a focal point for understanding bacterial resistance mechanisms. Studies have demonstrated that certain bacterial species can develop resistance through enzymatic modification or efflux pumps that expel the antibiotic from the cell. Understanding these pathways has paved the way for novel strategies to overcome resistance, including combination therapies that involve Kanamycin A with other agents.

The application of high-throughput screening technologies has further accelerated the discovery of new antibiotics derived from natural products like Kanamycin A. These technologies allow researchers to rapidly test thousands of compounds for their antimicrobial properties, significantly reducing the time required to identify potential candidates for further development. The integration of computational methods, such as molecular docking and structure-based drug design, has enhanced the precision of these screenings, leading to more targeted and effective antibiotic development.

Moreover, Kanamycin A has found utility in molecular biology research as a selective agent in genetic engineering experiments. Its ability to kill bacteria that have not been transformed with desired genetic material makes it an invaluable tool for ensuring the purity of transformed cell populations. This application underscores its versatility beyond clinical use, highlighting its importance in both therapeutic and scientific contexts.

The environmental impact of antibiotics like Kanamycin A is another area of growing interest. Research has explored the persistence and degradation rates of these compounds in various ecosystems, emphasizing the need for sustainable practices in antibiotic production and disposal. Efforts are underway to develop environmentally friendly methods for synthesizing antibiotics, including biocatalytic processes that minimize waste and energy consumption.

Future directions in Kanamycin A research include exploring its potential in combination therapies with other antimicrobial agents or even antiviral drugs. The synergistic effects observed in such combinations could lead to more robust treatments against infectious diseases. Additionally, investigating the compound's role in modulating immune responses may open new avenues for treating inflammatory conditions and autoimmune diseases.

In conclusion, Kanamycin A (CAS No. 59-01-8) remains a vital compound in modern medicine and research due to its potent antimicrobial properties and diverse applications. Ongoing studies continue to uncover new aspects of its mechanism of action, resistance profiles, and potential therapeutic uses. As the global landscape of infectious diseases evolves, compounds like Kanamycin A will play an increasingly critical role in addressing emerging challenges and improving patient outcomes.

59-01-8 (Kanamycin A) Related Products

Recommended suppliers